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Tyrosine phosphorylation, a highly regulated post-translational modification, is car-
ried out by the enzyme tyrosine kinase (TK). TKs are important mediators in signaling
cascades, facilitating diverse biological processes in response to stimuli. TKs may
acquire mutations leading to malignancy and are viable targets for anti-cancer drugs.
Mast/stem cell growth factor receptor KIT is a TK involved in cell differentiation,
whose dysregulation leads to various types of cancer, including gastrointestinal stro-
mal tumors, leukemia, and melanoma. KIT can be targeted by a range of inhibitors
that predominantly bind to the inactive state of the enzyme. A mutation Y823D in
the activation loop of KIT is known to be responsible for the loss of sensitivity to
some drugs in metastatic tumors. We used all-atom molecular dynamics simulations
to study the impact of Y823D on the KIT conformation and dynamics and compared
it to the effect of phosphorylation of Y823. We simulated in total 6.4 μs of wild-type,
mutant and phosphorylated KIT in the active- and inactive-state conformations. We
found that Y823D affects the protein dynamics differently: in the active state, the
mutation increases the protein stability, whereas in the inactive state it induces local
destabilization, thus shifting the dynamic equilibrium towards the active state, alter-
ing the communication between distant regulatory regions. The observed dynamics
of the Y823D mutant is similar to the dynamics of KIT phosphorylated at position
Y823, thus we hypothesize that this mutation mimics a constitutively active kinase,
which is not responsive to inhibitors that bind its inactive conformation.
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1 | INTRODUCTION
The human genome contains 518 genes encoding kinases, of which
90 encode protein tyrosine kinases (TKs).1,2 TKs are enzymes that
phosphorylate a tyrosine residue of a target protein or phosphorylate
their own tyrosines, leading to conformational changes and, typically,
activation of downstream signaling cascades. Thus, TKs function as
“on” or “off” switches in many cellular processes. The 90 TKs can be
grouped into two classes: 58 of them belong to receptor tyrosine
kinases (RTKs) and 32 of them are non-receptor tyrosine kinases
(NRTKs). The major difference between these two classes is that the
NRTKs, in contrast to RTKs, do not have the extracellular domain that
is responsible for binding of extracellular ligand molecules. From here
on, we will focus on RTKs. RTKs are cell surface receptors for several
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growth factors, hormones and cytokines. Beside the ligand-binding
extracellular domain, RTKs contain a single transmembrane helix sepa-
rating the intracellular TK domain from the extracellular domain.
The RTK activation involves binding of a ligand to the RTK monomer
leading to the dimerization of the receptors. Upon binding of a ligand to
the extracellular domain the receptor undergoes extensive conforma-
tional changes that induce and stabilize the receptor dimerization leading
to the stimulation of the kinase activity in the intracellular domain, thus
resulting in auto-phosphorylation of tyrosine residues in it. The intracel-
lular TK domain has a bi-lobar structure, with an ATP binding cleft
located between the N- and C-terminal lobes that catalyzes the auto-
phosphorylation and trans-phosphorylation of tyrosine residues and a
kinase insert domain.3 The N-lobe (residues 582-692) is composed of
antiparallel β sheets adjacent to the α-helix (αC-helix) and the C-lobe (res-
idues 763-935) shows predominantly the α-helical structure (Figure 1).
The C-lobe contains the G-helix that binds the kinase substrate and an
activation loop (A-loop) (residues 810-835) that begins with a highly con-
served DFG (residues 810-812) motif. The major autophosphorylation
sites are in the juxtamembrane region (JMR, residues 547-581) and in
the kinase domain (KD, residues 582-935).3 The phosphorylated tyrosine
residues of the activated receptor now act as a binding site for proteins
containing the Src homology 2 (SH2) and phosphotyrosine binding (PTB)
domains.
In its unphosphorylated state, the intracellular TK domain exists in
its inactive auto-inhibited conformation (Figure 1). As part of the activa-
tion process upon ligand binding to the extracellular domain, the A-loop
adjacent to the active site in the inactive state switches from its
auto-inhibitory position to a more open form. During this process, the
DFG motif at the N-terminus of the A-loop flips its side chain away from
the ATP binding site, thus allowing for binding of the ATP and Mg2+
cofactors. Following these structural changes, the JMR unwinds from its
buried position in the TK domain to a solvent-exposed position, and the
αC-helix undergoes orientational changes breaking the contacts with the
JM-B fragment of the JMR. Along with JM-B, the JM-Z fragment is also
involved in blocking the αC-helix, which regulates the catalytic activity of
the kinases4 and prevents the A-loop from adopting an active conforma-
tion, restricting the inter-lobe flexibility.
In 1984, the first connection between a viral oncogene, a mutated
RTK and human cancer was established.5 Since then it is well-
established that aberrant signaling by RTKs is critically involved in
human cancer. The profuse knowledge of the structure and activation
mechanism of RTKs and the variations of TK signal transduction path-
ways in proliferative disorders led to the idea that tyrosine kinase
inhibitors (TKIs) could have anticancer effects.2,6 As a result, the
development of target-specific TKIs and new anticancer drug discov-
ery has become a hot area of anticancer research.
Most of the TKIs are small hydrophobic compounds that can rap-
idly reach their specific intracellular targets and inhibit the activation
of the related TKs.2,7,8 Unfortunately, the patients who gained
remarkable benefit from the TKI therapy started showing increasing
evidence of acquired resistance.9-11 It is primarily due to the acquired
secondary drug-resistance mutations that change the protein confor-
mation and alter the drug binding site, leading to the therapy failure
and cancer relapse. These mutations may alter the tightly controlled
F IGURE 1 Structure of KIT cytoplasmic region. 3D structures of the native receptors in the inactive state (PDB id: 1T45) and in the active
state (PDB id: 1PKG) are represented as cartoons. The N-lobe in blue, the C-lobe in green, the αC-helix in cyan, the A-loop in red, and the JMR in
orange colors. The DFG motif and the mutation site Y823D are represented in sticks (yellow)
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functions of the protein including ligand binding, conformational tran-
sitions, allosteric regulation, inducing resistance to several first and
second line drugs.2,3,12 However, the exact molecular mechanisms of
the changes induced by such mutations are still not well understood.
KIT is a stem cell factor (SCF) receptor also known as proto-
oncogene receptor tyrosine kinase, a member of the class III of RTKs.
The activation of KIT proceeds similarly to other RTKs: a SCF mole-
cule binds to a KIT monomer in the extracellular domain leading to
dimerization, activation, and autophosphorylation of tyrosine residues
in the KD.13-16 During this process, the key regulatory regions in the
TK domain undergo extensive conformational changes. A gain-of-
function or an acquired secondary drug resistance mutation in the TK
domain can activate the protein in the absence of the ligand. D816V
is one of such mutations that has been studied extensively using the
molecular dynamics (MD) simulations.16-19 It has been shown that this
mutation in the inactive state disrupts the communication between
the A-loop and the JMR17,18 and causes a partial folding of a con-
served 310 helices in the A-loop leading to the changes in the local H-
bond network,16 the global structural reorganization of the JMR, and
constitutive activation of the protein.20 KIT harboring this mutation is
resistant towards several drugs including imatinib and sunitinib.21-23
Y823D is also a similar gain-of-function or a secondary mutation
which has been reported in several clinical cases.24,25 Y823D can con-
stitutively activate the PI3K/AKT, RAS-ERK, and JAK/STAT pathways
leading to tumorigenesis by inducing cell proliferation, growth pro-
gression or migration.21,26,27 This mutation is associated with various
forms of cancer including gastrointestinal stromal tumors, testicular
seminomas, melanogenesis, and in hematopoiesis.20,21,28 Yet, very lit-
tle is known about the impact of this mutation on the protein confor-
mational changes crucial for activation and ligand binding.
It has been reported that Y823D can cause stabilization of the
active conformation of the protein and that it is also responsible for
loss of sensitivity to drugs in metastatic tumors.29 This mutation is
located in the A-loop of the KD and occurs at the only tyrosine resi-
due in the A-loop. There exists literature evidence that this tyrosine
residue in the A-loop is the last residue that undergoes
autophosphorylation,15 suggesting it might not play a role in the acti-
vation mechanism. However, it has been shown that this tyrosine resi-
due is essential for the regulation of the kinase activity.15,23
In this present study, we explored the impact of the Y823D muta-
tion and tyrosine phosphorylation on protein conformation using MD
simulations. Specifically, we aimed to understand the differences in
dynamics within and between the different states of the protein,
which will enable us to identify the conformational changes that are
crucial for the activation and ligand binding.
2 | MATERIALS AND METHODS
2.1 | Target selection
We retrieved the crystallographic structures of the wild-type
(WT) inactive and active state of KIT protein from the Protein Data
Bank (PDB id of inactive state 1T45 and active state 1PKG).30 The
water molecules in the crystal structures were retained for the MD
simulations. The missing atoms in the crystal structure of the active
state of the protein were added using MODELLER 9.1731,32 and the
phosphorylated tyrosine residues at position 568 and 570 were
modeled back to their unphosphorylated state. In silico, substitution
of Tyr (Y) to Asp (D) at position 823 was performed using MODELLER
with the corresponding WT structures as the template for both active
and inactive states. Tyr (Y) at position 823 was also phosphorylated in
both monoanionic (TP1) and dianionic (TP2) states using CHARMM-
GUI.33-35 Generated models of the KIT, its MU Y823D, and two phos-
phorylated versions (TP1, TP2) are referred to as KIT-AWT, KIT-AMU,
KIT-ATP1, KIT-ATP2 and KIT-IWT, KIT-IMU, KIT-ITP1, and KIT-ITP2 for
active and inactive states, respectively.
2.2 | Preparation of the systems
MD simulations were performed using the GROMACS software pack-
age version 5.1.436 using two force fields, Amber99SB*-ILDN37,38 and
CHARMM36.39 The molecular systems KIT-AWT and KIT-AMU, KIT-
IWT and KIT-IMU were parameterized using the Amber99SB*-ILDN
force field.37,38 In a separate set, all generated models were parame-
terized using the CHARMM36 force field,39 and these variants are
further referred to as KIT-A*WT, KIT-A*MU, KIT-A*TP1, KIT-A*TP2 and
KIT-I*WT, KIT-I*MU, KIT-I*TP1, KIT-I*TP2. The molecules were centered
in a cubic box with a 1.5 nm buffer, under periodic boundary condi-
tions and the systems were explicitly solvated with TIP3P water mole-
cules. Counterions40 ClJ and NaJ for Amber99SB*-ILDN force field
simulations and Cl and Na for CHARMM36 force field simulations
were added when necessary to neutralize the overall charge
(0.15 mol/L concentration). Energy minimization for each of the
molecular systems was performed using the steepest descent algo-
rithm. A maximum of 50 000 steps was performed until a maximum
force of 1000.0 kJ mol−1 nm−1 was achieved. Following the energy
minimization, each of the molecular systems was subjected to two
consecutive steps of equilibration procedure. At first, each system
was maintained at a temperature of 310 K during the NVT ensemble
for 100 ps with a time step of 2 fs, followed by a 100 ps simulation in
the NPT ensemble with a time step of 2 fs maintaining the pressure at
1 bar to equilibrate the system.
2.3 | Production of trajectories
After the NPT ensemble simulations, we performed a total of
64 100 ns-long production simulations with eight replicas for each of
the systems parameterized by Amber99SB*-ILDN force field and four
replicas for each of the systems parameterized by CHARMM36 force
field. The coordinates were recorded at every 100 ps. The tempera-
tures of solute and solvent were separately coupled to the velocity
rescale thermostat (modified Berendsen thermostat)41 at 310 K with a
relaxation time of 0.1 ps. The pressure was maintained at 1 atm by
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isotropic coordinate scaling with a relaxation time of 5 ps using
Parrinello-Rahman barostat.42 A time step of 2 fs was used to inte-
grate the equations of motion based on the leap-frog algorithm.43
Lennard-Jones interactions were set to a cut-off of 1.4 nm, and the
Particle Mesh Ewald (PME) method44 was used to treat long-range
electrostatic interactions. All bonds were constrained using P-LINCS
algorithm.45
2.4 | Analysis of the trajectories
The resulting trajectories from the simulations were analyzed using
various tools including the tools from the GROMACS package. From
the root mean square deviation (RMSD) profiles, the first 10 ns were
considered to be a part of the equilibration process, therefore it was
ignored, and the last 90 ns were retained for further analysis except
for hydrogen bond (H-bond) calculations.
The secondary structure profiles were calculated using gmx
do_dssp program available in GROMACS that uses the DSSP algo-
rithm.46 The calculation was performed over the concatenated trajec-
tories of each system. The consensus secondary structure was
defined as the type of secondary structure most prevalent at a given
position over the whole simulation time (only α-helices and β-strands
were considered) and visualized using Biotite.47 The secondary struc-
ture elements such as 310-helix, pi-helix, bend, turn, bridge, and coil
were jointly marked as coil.
To study the coupling between JMR and KD in KIT proteins, two
characteristic distances were monitored over the MD simulations of
each system. The distance d1 between the centroid of the JM-B
region (residues 547-559 as C1) and the centroid of the residues in
the N-lobe (residues 582-692 as C1') and the distance d2 between
the centroid of the JM-S region (residues 560-570 as C2) and the cen-
troid of the residues in the C-lobe (residues 763-935 as C2').
From the MD trajectories, the H-bonds between key residues
were calculated using the program gmx hbond available in GROMACS.
H-bonds were defined with a DHA angle cutoff of 120 and a donor-
acceptor distance cutoff of 3.5 Å. The mean and standard error of the
mean was calculated using R.48
For the molecular systems parameterized by the CHARMM36
force field, we performed analysis of RMSD, RMSF, secondary struc-
ture, H-bonds, and principal component analysis.
2.5 | Principal component analysis
Principal component analysis (PCA) is a method for reducing the
dimensionality of a complex system. Before performing PCA, the
concatenated trajectories from replica simulations were superimposed
to minimize the variance over the ensemble.49 The key idea of PCA is
to identify the significant eigenvectors which define the dominant col-
lective motions. The calculation was performed using the gmx covar
module of GROMACS. The overlap between the first 10 modes of
each trajectory was calculated using the gmx anaeig module of
GROMACS. The perturbations of the systems can be described in
terms of only a few principal components by ordering the eigenvalues
of the diagonalized covariance matrix in a descending fashion. Thus,
PCA helps to extract the large-scale motions from MD trajectories by
isolating the dominant modes of internal motion.
2.6 | Mutual Information
Calculating mutual information (MI) between individual pairs of amino
acids allows to identify whether the changes in the pairs of conforma-
tional distributions of these amino acids are correlated, linearly or non-
linearly. It is assumed that such correlated changes can cause perturba-
tions to the energy landscape. Both backbone and side chain torsion
angles (φ, ψ , and χ) were used to study the correlated motion between
pairs of residues as they are assumed to contain the functionally relevant
perturbations and conformational changes.50 The MI between them was
estimated using MutInf method50 that allows us to capture significant
concerted conformational changes of two residues as it focuses on tor-
sion angles that are responsible for the low-frequency motions. We used
a bin size of 24 degrees to obtain discrete distributions of the dihedral
angles. The MI between pairs of residues are calculated as the individual
sum of their entropies and subtracting it from their joint entropy over
adaptive partitioning. Each MI value was then compared to the back-
ground distribution of all MI values for all pairs of amino acids in the tra-
jectories of the WT and mutant structures. A P-value threshold of .01
was applied for filtering of significant correlations (for more details refer
to the original article).50
To account for propagated error when comparing MI of WT and
MU, bootstrap sets were created, following the procedure as
described previously.51 For this purpose for each dataset torsion
angles were extracted from individual trajectories using the gmx g_chi
command in GROMACS and sampled with replacement n frames from
a simulation of length n. This procedure was repeated 10 times for
each of the replicas while preserving the same order across the differ-
ent dihedral angles and simulation runs. The mean and standard devia-
tion, μMIres and sdMIres, were then calculated for every pair of
correlated residues MIres from the 10 bootstrap sets. When comparing
the MI in the wild-type and mutant complexes, MIresWT and MIresMU,
only those residue pairs were retained, for which the following condi-
tion holds,







Where, N is the total number of independent replica simulations.
To further eliminate the noise and weak interactions between corre-
lated residues, a cutoff (MI >0.8 kT for the inactive state, and MI
>1.7 kT for the active state) was chosen, so that pairs with a small
absolute difference between mean values were disregarded. This step
was necessary to select only the correlated residues that have largely
different mean MI values when comparing the WT and MU
simulations.
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2.7 | Partial least-squares regression
Partial least-squares regression (PLS) was applied to identify the col-
lective modes of internal dynamics associated with an external order
parameter of functional interest using the functional mode analysis
tool.52 For this analysis, the coordinates of the backbone atoms, back-
bone atoms without JMR region and all protein atoms excluding
hydrogen atoms were used as inputs to build the statistical models.
The constants 0 and 1 corresponding to the trajectories in WT and
MU simulations were used as the read-out variable to be
estimated.
To validate the statistical models generated, we applied the fol-
lowing adapted k-fold cross-validation (CV) technique for WT and MU
trajectories separately in the active and inactive states, again follow-
ing the procedure described before.51 The trajectories of WT and MU
of the inactive state KIT protein were concatenated and sup-
erimposed to minimize the variance over the ensemble.49 The
resulting trajectory was divided into four equal parts. Three parts of
the data with the labeled input containing equal parts from both WT
and MU were then used in each iteration to train a model. Based on
this we made predictions for the last part. The final number of PLS
modes/components were chosen based on the Pearson correlation
calculated between the actual and the predicted values, with a
compromise between the number of modes, the complexity and the
quality of prediction using the “elbow method.”53,54
3 | RESULTS
Structural features and internal dynamics of the KIT molecular sys-
tems were analyzed to investigate the differences between the con-
formations induced by the gain-of-function mutation Y823D and the
two variants of phosphorylation of Y823.
3.1 | General observations
The Root Mean Square Deviations (RMSDs) were calculated for the
backbone atoms and the key structural elements (αC-helix, JMR, and
A-loop) (Figure 2A and Figure S1A) of the kinase domain (KD) to
ascertain the time evolution of the structure. The backbone RMSD
profiles of the inactive and active states show that they conform
closely to their initial crystallographic structures. The RMSD mean
values were in the range of 0.16 to 0.25 nm for inactive state and
0.36 to 0.52 nm for active state in trajectories resulting from simula-
tions using both Amber99SB*-ILDN and CHARMM36 force fields.
F IGURE 2 A, The RMSD values calculated for backbone atoms (black), αC-helix (brown), A-loop (red), and JMR (orange) from all eight
trajectories of MD simulations of KITWT and KITMU in both the states (active and inactive). B, The RMSF values computed on the backbone atoms
of the concatenated trajectory of MD simulations of KITWT (black) and KITMU (red). The RMSF values of the A-loop are given in the insert. The
average conformation of the, C, active state KIT and D, inactive state KIT is represented as tubes. The highly flexible regions are shown in red,
highly stable residues are shown in blue, and the intermediate flexible residues are shown in white. The size of the tube is proportional to the
observed RMSF values in those regions, respectively
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RMSD profiles show the conformational drift of the JMR in the inac-
tive state of the protein is larger than the other KIT regions. In the
active state, along with JMR, A-loop also was observed to have a large
RMSD, whereas the αC-helix is observed to be rigid in both the
states.
The protein flexibility was estimated by the root mean square
fluctuations (RMSFs) averaged over time for every residue. The RMSF
values of the backbone atoms (Figure 2B and Figure S1B) were com-
parable between different systems, ranging from 0.1 to 0.3 nm in the
inactive state and 0.1 to 0.4 nm for the active state in trajectories
resulting from simulations using both Amber99SB*-ILDN and
CHARMM36 force fields. From the RMSF plot (Figure S1B) we can
also observe how the MU and phosphotyrosines simulations con-
verge, showing that the Y823D mutation mimics the presence of a
phosphotyrosine. Both variants of the phosphotyrosine behave very
similarly in the simulation. Further, we can also observe that the WT
and MU simulations of both active and inactive states performed
using two different force fields agree very well with each other
(Figure S1B and S2).
3.2 | Secondary structure analysis
Upon analyzing the trajectories resulting from simulations using both
Amber99SB*-ILDN and CHARMM36 force fields, we observe that the
mutation does not significantly alter the secondary structure of JMR
in both states of the protein (Figures S3 and S4) compared to its WT,
but we observe slight changes in the secondary structure type during
our simulations.
The mutation Y823D is located in the A-loop and induces local
fluctuations in the inactive state of the protein. Unlike, other second-
ary mutations such as D816V/H/N/Y17,20 in the A-loop, the mutation
Y823D does not destabilize the 310-helix in the segment 817 to
819 in the trajectories resulting from Amber99SB*-ILDN force field (-
Figure S5), whereas in the active state almost all secondary structure
in the A-loop is lost. The 310-helix is better retained in the MU simula-
tion with the CHARMM36 force field, whereas in KIT-I*TP1, KIT-I*TP2
trajectories resulting from CHARMM36 force field (Figure S6), we
observe very little secondary structure in the A-loop. The 310-helix in
the A-loop is only observed in the inactive state of the protein and
destabilization of this segment has been reported to be associated
with the disruption of its integrity.20 Such destabilization of key
regions in the A-loop is associated with a major contribution to the
loss of drug sensitivity.20
3.3 | Dynamic behavior of receptors
The effect of the mutation on the collective dynamic behavior of
various KIT structural elements is markedly different in the active
and inactive states. The computed scalar products between the
first 10 PCA modes of KIT inactive state proteins indicate that the
collective motions differ between them (Figure S7A). It is
interesting to compare the dynamics of the WT and MU protein in
each state.
When the trajectories of the KIT-IWT and KIT-IMU are projected
into the subspace spanned by their first two PCs (Figure 3A), one can
observe a large overlap of the WT and MU parts of the trajectories,
and a considerable shift along the PC1 axis. Modes 1 and 2 of KIT-IMU
display a slightly higher amplitude compared to KIT-IWT (Figure S7B),
indicating increased flexibility of the protein upon mutation. These
modes correspond to atomic motions (Figure 3B,C) of JMR coupled to
deformations of the KD in the N-lobe, αC-helix, residues 626-631
preceding the αC-helix, orientational changes in the A-loop and the G-
helix in the C-lobe. Principal modes of KIT-IMU describe atomic
motions of JM-B coupled with a twist motion of the N-lobe and a dis-
placement of the A-loop and G-helix in the C-lobe. This displacement/
outward motion of the A-loop is not characteristic for the active con-
formation. The RMSF analysis along the individual modes (eigenvec-
tors) reveals that the JMR, A-loop portions are dominant in the total
backbone fluctuations along with kinase insert domain and minor per-
turbations of the αC-helix (data not shown).
Mapping KIT-AWT and KIT-AMU into the subspace spanned by
the first two principal components of their concatenated trajectories
shows that these trajectories occupy very different regions in it
(Figure 3D). Analysis of the first eigenvectors of KIT in active state
shows that there is a good agreement between the first principal mode
of KIT-AWT and KIT-AMU, but not so for the second mode (Figure S7C).
Accordingly, the WT trajectory occupies a similar region as the MU tra-
jectory along PC1, but differs much along PC2. The first eigenvalues
for both WT and MU trajectories in the active state are much higher
than those for the inactive state, indicating a generally higher flexibility
of the protein in the active state (Figure S7D). In KIT-AWT the first
mode is associated with displacement of JMR, A-loop, and unwinding
twist motion of the N-lobe (Figure 3E,F), while the KIT-AMU experi-
ences a conformational change in the JMR, its A-loop curtails from its
elongated conformation, and an opposite twisted motion along an axis
passing between the middle of the N- and C-lobe happens. The RMSF
analysis along the first eigenvector shows that the JMR, kinase insert
domain and the A-loop contribute the most to the backbone fluctua-
tions in both KIT-AWT and KIT-AMU (data not shown).
PCA on the inactive state trajectories from CHARMM36 force
field simulations confirm the similarity in the conformational distribu-
tion of the mutant and the phosphotyrosine simulations based on the
projection onto the subspace defined by the first two PCs (PC1 and
PC2; Figure S8).
3.4 | Coupling between JMR and KD in receptors
To check the possible coupling between JMR with KD in both states
of the protein, their relative positions were characterized using two
geometrical distances d1 and d2 (See Section 2). Monitoring of these
distances over the course of the MD indicates that the d1 and d2
distributions (Table 1) in the inactive and active states of the KIT are
very similar for both WT and MU. This demonstrates that the JMR is
6 SRIKAKULAM ET AL.
tightly coupled to the KD in both KIT conformations. The same can be
observed in the PCA analysis we observed that the A-loop is responsi-
ble for the dominant fluctuations during the simulations of the active
state (Figures 3E-F). Apart from these fluctuations, there are no major
conformational changes observed and the computed d2 distance devi-
ation between KIT-AWT and KIT-AMU is also negligible.
Frequency of H-bonds between key residues that maintain the
conformation of the KIT protein and the residues that are known to
be involved in establishing the allosteric communication between
JMR and KD, such as H-bond between D792 and Y82316,17,20,56 was
measured (Tables 2 and 3). In KIT-IWT, JMR binds to the C-lobe of KD
through stable H-bonds V560…N787, K558…I789, Y568…F848 and
Y570…Y846. These H-bonds are preserved in the mutated and phos-
phorylated structures of KIT indicating a strong coupling and stabiliza-
tion of the JMR attachment to KD and of the internal JMR contacts.
These data are consistent with the data from the coupling analysis
between JMR and KD.
The signal from A-loop to the JMR is propagated through the
C-loop, with Y823 as a key intermediate residue.18 The corresponding
H-bonds are affected upon the Y823D mutation and phosphoryla-
tion. The H-bond between residues Y823 and D792 is completely
lost in KIT-IMU, KIT-I*MU, KIT-I*TP1, and KIT-I*TP2 due to the chan-
ged properties of the residue at position 823. The interaction
between D792 and N797 is also observed less frequently. How-
ever, the H-bond between D792 and H790 is not affected. Such
modification in the local interaction network of the C-loop has
been shown to be accompanied by a decreased communication to
the distant KIT regulatory elements.18 These observations suggest
that the allosteric communication in the KIT inactive state between
the A-loop and JMR is disrupted by the mutation Y823D in the
A-loop. A beta-turn motif (residues 820-823) supported by a
H-bond D820…N822 also disappears in the mutated and phosphor-
ylated structures. It is known that this beta-turn motif is stabilized
by the H-bond D820…N822 in the protein inactive state, and dis-
ruption of this H-bond results in the unfolding of the beta-turn
motif.18 Importantly, we also observe different χ angle distributions
of D810 and F811 of the DFG motif between the KIT-IWT and
KIT-IMU (Figure S10).
F IGURE 3 PCA of KIT inactive and active states. The atomic motions are shown as interpolation between the extremes along the first
principal component of the, B,C, inactive state and, E,F, active state. The conformation distribution of different states (WT: cyan, MU: red) of KIT
projected onto the subspace defined by the first two principal components (PC1 and PC2) of the concatenated WT and MU trajectories in the
active, A, and in the inactive states, D
TABLE 1 Average distance between
centroids of (d1) JM-B and N-lobe and
(d2) JM-S and C-lobe
KIT-IWT KIT-IMU KIT-AWT KIT-AMU
d1 1.92 ± 0.01 1.92 ± 0.01 2.05 ± 0.04 2.08 ± 0.05
d2 2.3 ± 0.02 2.3 ± 0.02 3.05 ± 0.11 3.03 ± 0.09
Note: ± indicates standard error across independent simulations.
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In the KIT active state the residues D792, H790, and N797 of the
C-loop (catalytic loop) are involved in the formation of a local H-bond
interaction network that is stable along the MD trajectories. Further,
the H-bond analysis shows a stabilization of JMR, A-loop and C-loop
suggesting that the mutation Y823D and the phosphorylation of
Y823 cause stabilization of the active state. In particular, the H-bonds
R815…Y(D)823 and Y(D)823…Y846 are observed more frequently in
all simulations for the mutated and phosphorylated KIT in the active
state. These H-bonds are located either in the A-loop or connect the
A-loop and the C-lobe, probably stabilizing their mutual orientation.
On the contrary, in the mutated and phosphorylated protein in the
inactive state, the interactions of JMR with the KD is preserved, while
the A-loop is displaced and destabilized.
3.5 | Changes in the correlated motions of amino
acid residues
The correlation between the motions of all pairs of residues emerges
from the various ways, in which they interact with one another.
Here, we investigated how the mutation Y823D alters the concerted
motion between residues, which in turn can affect the allosteric
communication between distant regulatory regions of KIT. To do so,
we computed the MI between trajectories of individual residues. MI
reflects the degree to which two random variables are linked; high MI
indicates a low uncertainty in one random variable given the informa-
tion about the other. Interestingly, in both active and inactive states,
most of the correlations are between distant residues (Figure 4A,D
and Figure S9). We can observe that there are only a few residues in
the mutated protein in the active state showing changes in the corre-
lated motion and that almost all the residues involved in the interac-
tions are between 8 and 21 Å apart from one another. Additionally, in
the inactive state, we see that the changes in the pattern of correlated
motions are much stronger in the mutant protein when compared to
the WT.
Further, analysis of the correlated motion of residues in the inac-
tive state and the active state revealed that certain residues act as
hubs connected to several other residues (Figure 4B,E). However, the
residues acting as hubs are not the same for active and inactive states,
indicating that the correlated motions are different in different con-
formations of the same protein and that mutation Y823D affects
these conformations differently. In the inactive state, the residues
N797 and R888 act as hubs interacting with several key residues
(D810, R815, R830, and M836) of the protein (Figure 4B), suggesting
TABLE 2 Average H-bond number
between residues in Amber99SB*-ILDN
force field simulations
JMR…C-lobe KIT-IWT KIT-IMU KIT-AWT KIT-AMU
V560…N787 1.067 ± 0.01 1.08 ± 0.01 0.001 ± 0 0.008 ± 0.01
K558…I789 1.80 ± 0.03 1.87 ± 0.03 0 0.25 ± 0.25
Y568…F848 0.29 ± 0.6 0.35 ± 0.12 0.04 ± 0.04 0
Y570…Y846 1.23 ± 0.23 1.09 ± 0.24 0 0
E640…F811 0 0 0.71 ± 0.14 0.55 ± 0.13
JMS
V569…E561 1.02 ± 0.06 1.21 ± 0.16 0 0
A-loop
V824…L831 2.022 ± 0.01 1.9 ± 0.06 0 0
R815…Y823 0.89 ± 0.22 0.09 ± 0.04 0.32 ± 0.16 0.733 ± 0.3
D820…N822 2.68 ± 0.08 1.65 ± 0.21 0.97 ± 0.22 0.98 ± 0.23
A-loop…C-lobe
Y823…R796 1.254 ± 0.23 1.1 ± 0.46 0 0
Y823…Y846 0 0 0.22 ± 0.08 0.42 ± 0.2
C-loop
D792…H790 1.931 ± 0.01 1.93 ± 0.02 1.53 ± 0.12 1.7 ± 0.07
H790…N797 0 0.13 ± 0.1 0.15 ± 0.1 0.16 ± 0.1
D792…N797 2.088 ± 0.1 1.83 ± 0.18 1.4 ± 0.16 1.53 ± 0.22
C-loop…A-loop
D792…Y823 1.20 ± 0.19 0 0 0
C-loop…C-lobe
N797…C809 0.56 ± 0.12 0.87 ± 0.15 0.85 ± 0.14 0.55 ± 0.17
C-lobe
L799…K807 2 ± 0 2 ± 0 2 ± 0 2 ± 0
Note: ± indicates standard error across independent simulations.
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that any change in the motion of these residues will affect the corre-
lated motion of the other residues. Similarly, in the active state, the
residues E554 and the highly conserved residue R815 act as hubs and
we also see that overall more residue pairs are involved in correlated
motions in the WT than mutant protein (Figure 4E). Among the resi-
dues whose motion was most affected by the mutation in the inactive
state are the residues of the inhibitor binding site and the conserved
C-loop residues (residues 568, 797, 810, and 815), P+1 loop (the loop
immediately following the A-loop, residues 830 and 836), critical resi-
due of the DFG motif (residue 810) and F-helix (residue 861).
In KIT-IWT, the signal from A-loop to the JMR is propagated
through the C-loop residues, where Y823 acts as an intermediate resi-
due.18 From MI data, we can observe how mutation in this position
has changed the communication between distant regulatory regions
in the protein. Thus, the modification in the local interaction network
of the C-loop that we observed in the H-bond analysis is accompanied
by a reduction in the efficient communication to the distant KIT regu-
latory elements. In the active state of KIT we notice a different pat-
tern, where none of the correlated motions below the threshold
(1.7 kT) involving the key residues were affected by the mutation
(Figure 5B).
3.6 | Partial least-squares regression
The functional mode analysis based on the partial least-squares (PLS)
regression method aids in differentiating the major collective motions
between the WT and MU proteins. As input, we used the coordinates
of the backbone atoms as they proved to have the most predictive
power when creating the statistical models for the inactive state (data
for other input types not shown). For the active state, none of the
input features were able to provide a satisfactory model that could be
used to differentiate the collective motions between the WT and
mutant proteins. Therefore, only the results for the inactive state of
the protein are discussed.
We used fourfold cross validation (CV) technique to obtain the
statistical models and measured the prediction quality through
Pearson correlation score between the true and predicted label for
a given input feature. We chose models composed of three PLS
components to study the changes in the collective motions of the
protein, which was sufficient in the CV scenario to achieve a corre-
lation of .75 (Figure S11). Mapping the PLS results onto the back-
bone of the inactive state of KIT (Figure 5) showed that the
mutation induced changes in the collective motions in the JM-B,
TABLE 3 Average H-bond number between residues in CHARMM36 force field simulations
JMR…C-lobe KIT-I*WT KIT-I*MU KIT-I*TP1 KIT-I*TP2 KIT-A*WT KIT-A*MU KIT-A*TP1 KIT-A*TP2
V560…N787 1.03 ± 0 1.11 ± 0.02 1.1 ± 0.05 1.1 ± 0.02 0 0 0.02 ± 0.02 0.05 ± 0.04
K558…I789 1.54 ± 0.07 2 ± 0.16 1.65 ± 0.13 1.34 ± 0.13 0 0.01 ± 0.01 0 0
Y568…F848 0.23 ± 0.09 0.59 ± 0.14 0.59 ± .028 0.74 ± 0.27 0 0 0 0
Y570…Y846 0.3 ± 0.12 0.16 ± 0.05 0.32 ± 0.06 0.06 ± 0.01 0 0 0 0
E640…F811 0 0 0 0 0.85 ± 0.14 0.73 ± 0.2 0.57 ± 0.13 0.84 ± 0.08
JMS
V569…E561 1.13 ± 0.28 1.11 ± 0.09 1.11 ± 0.05 1.17 ± 0.14 0 0 0 0
A-loop
V824…L831 2.02 ± 0.01 1.33 ± 0.08 1.94 ± 0.06 1.64 ± 0.22 0 0 0 0
R815…Y823 0.79 ± 0.39 0 1.14 ± 0.35 0.89 ± 0.46 0.05 ± 0.03 0.16 ± 0.04 0.31 ± 0.17 2.09 ± 0.66
D820…N822 2.24 ± 0.05 0.99 ± 0.22 0.79 ± 0.14 0.36 ± 0.09 0.34 ± 0.09 0.33 ± 0.08 0.49 ± 0.24 0.23 ± 0.08
A-loop…C-lobe
Y823…R796 1.16 ± 0.11 0.57 ± 0.27 2.11 ± 0.54 2.87 ± 0.05 0 0 0 0
Y823…Y846 0 0 0 0 0.03 ± 0.02 0.1 ± 0.05 0.83 ± 0.45 0.08 ± 0.05
C-loop
D792…H790 1.51 ± 0.02 1.35 ± 0.17 1.65 ± 0.1 1.32 ± 0.1 1.35 ± 0.13 1.11 ± 0.15 1.26 ± 0.15 1.53 ± 0.1
H790…N797 0 0 0 0 0.06 ± 0.06 0.18 ± 0.18 0.2 ± 0.11 0.03 ± 0.02
D792…N797 2.01 ± 0.08 1.71 ± 0.09 1.72 ± 0.08 1.73 ± 0.05 1.39 ± 0.22 1.29 ± 0.26 0.95 ± 0.2 1.49 ± 0.14
C-loop…A-loop
D792…Y823 1.3 ± 0.1 0 0.57 ± 0.25 0 0 0 0 0
C-loop…C-lobe
N797…C809 0.34 ± 0.04 0.33 ± 0.16 0.52 ± 0.12 0.2 ± 0.08 0.45 ± 0.11 0.61 ± 0.15 0.59 ± 0.35 0.4 ± 0.17
C-lobe
L799…K807 2 ± 0 2 ± 0 2 ± 0 2 ± 0 2 ± 0 2 ± 0 1.99 ± 0.01 1.99 ± 0.01
Note: ± indicates standard error across independent simulations.
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JM-S, A-loop, and αC-helix. In agreement with this, we observe the
same regions to undergo large shifts in the PCA analysis (see
above).
4 | DISCUSSION
This study presents a first application of MD simulation aimed at
understanding the effects of the mutation Y823D and phosphoryla-
tion of Y823, which confer resistance among others to imatinib and
sunitinib29,55-57 and is a secondary mutation in gastrointestinal stro-
mal tumors,29,57,58 both in the active and inactive states of KIT. Phos-
phorylation of Y823 is known to stabilize the active conformation of
the A-loop most probably by strong electrostatic interactions of the
phosphate group.24,25 Mutations such as Y823D, which mimic Y823
phosphorylation, were suggested to stabilize the active conformation
of the A-loop,24-26 which was confirmed in our analysis. In the active
state of the protein we observe that this mutation as well as phos-
phorylation of the tyrosine stabilizes the protein's active conformation
by strengthening the H-bonds, particularly the one between R815
and Y823 which is known to stabilize the active conformation of the
protein.59 In line with our observations, mutations in the A-loop are
known to disrupt the inactive conformation by introducing charged
side chains into the pocket.26,56,57
The different analyses of the trajectories that we performed for
both active and inactive conformations of the wild-type, mutant and
phosphorylated KIT all demonstrate different dynamics in the same
regions of the structure: the active site residues and other key resi-
dues in the A- and C-loops (Figure S12). These differences are promi-
nent for the inactive state of KIT, but are much less significant for the
active state. The dynamics of the mutant protein in all cases resem-
bles the dynamics of the kinase phosphorylated at the mutation site
F IGURE 4 A,D, Distance between correlated residues (MI greater than 0.8 kT in the inactive state and greater than 1.7 kT in the active state).
A gray line separates local (<6 Å) and long-range interactions. SD from the bootstrapped dataset is plotted as the error bars on top of the MI
values from the actual (not bootstrapped) simulations. B,E, Correlations with MI greater than 0.8 kT for the inactive state and MI greater than
1.7 kT for active state are only shown. C,F, Cylinders connecting residues represent differences in MI between those residues in MU (yellow) and
WT (gray), with the width of the cylinder proportional to the MI. Mutation site Y823D is represented as spheres in magenta
F IGURE 5 Interpolation between the extremes of the inactive state
PLS models. Blue-to-magenta bands correspond to the interpolation
along the mode that relates to the true label of simulation, WT and MU,
to the underlying differences in the protein motions
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Y823. This can probably be explained by the fact that the substitution
to a negatively charged aspartate in the position of Y823 mimics the
effect of the phosphorylation at position Y823.
The biological significance of these structural regions was previously
reported in the literature.18,60-62 In particular, the C-loop is highly con-
served in terms of structure and sequence among all kinases.60 Another
structural element, the F-helix, whose motion was also affected in our
analysis, was shown to play an important role in protein kinase active
structures, as it is considered as the central hub connecting key areas
such as the substrate binding residues and the C-loop. Also the regula-
tory and catalytic spines are located at the N and C termini of the F-
helix.18,61,62 This puts the perturbations observed through RMSF analysis
in the JM-B, JM-S, A-loop, and the residues preceding the αC-helix in
the inactive state and the local destabilization of the A-loop through loss
of H-bonds into a proper functional context. Most importantly, we
observe the loss of allosteric communication, as evident from the
changes in the hydrogen bond network reported above, between distant
regulatory domains namely, JMR and the A-loop, which may be detri-
mental for kinase regulation. As observed from this analysis, the mutation
Y823D and the phosphorylation of Y823 stabilize the active conforma-
tion of the protein by contributing to the formation of more stable H-
bonds in the A- and C-loops.
The concerted alterations that we observe in all simulations of
the inactive state may potentially indicate mechanisms that could
affect the binding of drugs. Multiple lines of evidence presented here
suggest that the changes in the structural conformation of the inactive
state protein correspond to its destabilization upon mutation as well
as phosphorylation and a shift of the dynamic equilibrium away from
the inactive state, which is a primary target for many drugs. For exam-
ple, imatinib specifically binds to the inactive state of KIT,59,63 thus
these changes in the key regions of the inactive state of the protein
may alter the binding and/or the sensitivity to it and other drugs that
specifically targets the inactive state of KIT.
5 | CONCLUSIONS
In our simulations, we found that the mutation Y823D as well as
phosphorylation at this position in the A-loop of the protein TK KIT
compromise the communication between key regulatory regions of
the inactive state protein and induces local destabilization due to the
loss and reduction of key H-bonds. Further, we also observed changes
in the correlated motion of amino acids, especially between the muta-
tion site and the active site residues and other key residues such as
D792, R815, and Y82316,20,59 in the A-loop and catalytic loop that are
involved in drug binding and allosteric communication.
In summary, we collected multiple pieces of evidence demon-
strating that the mutation Y823D shifts the conformational equilib-
rium towards the active state. This is likely to lead to activating the
downstream signaling cascades and enhancing the expression of anti-
apoptotic, cell proliferation, and growth expression genes. It is worth
noting that Y823 in KIT is homologous to Y393 in the Abl kinase,
where phosphorylation of this residue is known to destabilize the
inactive conformation of the A-loop.24 In our simulations, we confirm
a similar trend for the mutation Y823D in KIT by conducting simula-
tions with a phosphorylated tyrosine at this position. Thus, we suggest
that an analogous mechanism of resistance evolved in a homologous
kinase leading to similar pathologic consequences.
ACKNOWLEDGMENTS
The authors wish to acknowledge Michael Hutter, Mazen Ahmad, and
Nicolas Künzel for discussions and technical suggestions on simula-
tions; Alexander Gress and Sebastian Keller for critical reading of the
manuscript.
CONFLICT OF INTERESTS
TB is an employee of AstraZeneca and has stock ownership and/or stock
options or interests in the company.
ORCID
Sanjay K. Srikakulam https://orcid.org/0000-0002-1752-5060
Olga V. Kalinina https://orcid.org/0000-0002-9445-477X
REFERENCES
1. Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of
activation and signaling. Curr Opin Cell Biol. 2007;19(2):117-123.
https://doi.org/10.1016/j.ceb.2007.02.010.
2. Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase
inhibitors. Acta Pharm Sin B. 2011;1(4):197-207. https://doi.org/10.
1016/j.apsb.2011.10.007.
3. Hubbard SR, Till JH. Protein tyrosine kinase structure and function.
www.annualreviews.org. 2000
4. Li S, Covino ND, Stein EG, Till JH, Hubbard SR. Structural and bio-
chemical evidence for an autoinhibitory role for tyrosine 984 in the
juxtamembrane region of the insulin receptor. J Biol Chem. 2003;278
(28):26007-26014. https://doi.org/10.1074/JBC.M302425200.
5. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth fac-
tor receptor cDNA sequence and aberrant expression of the amplified
gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418-425.
https://doi.org/10.1038/309418a0.
6. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer ther-
apy. J Pharmacol Exp Ther. 2005;315(3):971-979. https://doi.org/10.
1124/jpet.105.084145.
7. Sekhon N, Kumbla RA, Mita M. Chapter 1 - current trends in cancer
therapy. In: Gottlieb RA, Mehta PK, eds. Cardio-Oncology. Boston:
Academic Press; 2017:1-24. https://doi.org/10.1016/B978-0-12-
803547-4.00001-X.
8. Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors:
multi-targeted or single-targeted? World J Clin Oncol. 2011;2(2):80-
93. https://doi.org/10.5306/wjco.v2.i2.80.
9. Rosenzweig SA. Acquired resistance to drugs targeting tyrosine
kinases. Adv Cancer Res. 2018;138:71-98. https://doi.org/10.1016/
bs.acr.2018.02.003.
10. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibi-
tors and implications for therapeutic strategies. Clin Cancer Res off J
Am Assoc Cancer Res. 2014;20(9):2249-2256. https://doi.org/10.
1158/1078-0432.CCR-13-1610.
11. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase
inhibitors during cancer therapy. Curr Opin Genet Dev. 2008;18(1):73-
79. https://doi.org/10.1016/j.gde.2008.01.004.
12. Barouch-Bentov R, Sauer K. Mechanisms of drug-resistance in
kinases. Expert Opin Investig Drugs. 2011;20(2):153-208. https://doi.
org/10.1517/13543784.2011.546344.
SRIKAKULAM ET AL. 11
13. Roskoski R. Structure and regulation of KIT protein-tyrosine kinase—
the stem cell factor receptor. Biochem Biophys Res Commun. 2005;
338(3):1307-1315. https://doi.org/10.1016/j.bbrc.2005.09.150.
14. Shi X, Sousa LP, Mandel-Bausch EM, et al. Distinct cellular properties
of oncogenic KIT receptor tyrosine kinase mutants enable alternative
courses of cancer cell inhibition. Proc Natl Acad Sci. 2016;113(33):
E4784-E4793. https://doi.org/10.1073/pnas.1610179113.
15. Mol CD, Lim KB, Sridhar V, et al. Structure of a c-kit product complex
reveals the basis for kinase transactivation. J Biol Chem. 2003;278
(34):31461-31464. https://doi.org/10.1074/jbc.C300186200.
16. Da P, Figueiredo S, Gomes C, et al. Differential effects of CSF-1R
D802V and KIT D816V homologous mutations on receptor tertiary
structure and allosteric communication. PLOS One. 2014;9(5):e97519.
https://doi.org/10.1371/journal.pone.0097519.
17. Laine E, Chauvot de Beauchêne I, Perahia D, Auclair C, Tchertanov L.
Mutation D816V alters the internal structure and dynamics of c-KIT
receptor cytoplasmic region: implications for dimerization and activa-
tion mechanisms. Verkhivker GM. PLoS Comput Biol. 2011;7(6):
e1002068. https://doi.org/10.1371/journal.pcbi.1002068.
18. Laine E, Auclair C, Tchertanov L. Allosteric communication across the
native and mutated KIT receptor tyrosine kinase. Nussinov R. PLoS
Comput Biol. 2012;8(8):e1002661. https://doi.org/10.1371/journal.
pcbi.1002661.
19. Da Silva Figueiredo Celestino Gomes P, Chauvot De Beauchêne I,
Panel N, et al. Insight on mutation-induced resistance from molecular
dynamics simulations of the native and mutated CSF-1R and KIT.
PLoS ONE. 2016;11(7):e0160165. https://doi.org/10.1371/journal.
pone.0160165.
20. Chauvot de Beauchêne I, Allain A, Panel N, et al. Hotspot mutations
in KIT receptor differentially modulate its allosterically coupled con-
formational dynamics: impact on activation and drug sensitivity.
Nilges M, ed. PLoS Comput Biol. 2014;10(7):e1003749. https://doi.
org/10.1371/journal.pcbi.1003749.
21. Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ,
Ahmadipour F. Receptor tyrosine kinase (c-kit) inhibitors: a potential
therapeutic target in cancer cells. Drug Des Devel Ther. 2016;10:
2443-2459. https://doi.org/10.2147/DDDT.S89114.
22. Caenepeel S, Renshaw-Gegg L, Baher A, et al. Motesanib inhibits kit
mutations associated with gastrointestinal stromal tumors. J Exp Clin
Cancer Res CR. 2010;29(1):96. https://doi.org/10.1186/1756-9966-
29-96.
23. Agarwal S, Kazi JU, Mohlin S, Pa ahlman S, Rönnstrand L. The activa-
tion loop tyrosine 823 is essential for the transforming capacity of
the c-kit oncogenic mutant D816V. Oncogene. 2015;34(35):4581-
4590. https://doi.org/10.1038/onc.2014.383.
24. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to
targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004;3(12):
1001-1010. https://doi.org/10.1038/nrd1579.
25. Wang CM, Fu H, Zhao GF, et al. Secondary resistance to imatinib in
patients with gastrointestinal stromal tumors through an acquired KIT
exon 17 mutation. Mol Med Rep. 2009;2(3):455-460. https://doi.org/
10.3892/mmr_00000121.
26. Agarwal S, Kazi JU, Rönnstrand L. Phosphorylation of the activation
loop tyrosine 823 in c-kit is crucial for cell survival and proliferation.
J Biol Chem. 2013;288(31):22460-22468. https://doi.org/10.1074/
jbc.M113.474072.
27. Maleddu A, Pantaleo MA, Nannini M, Saponara M, Lolli C, Biasco G.
Mechanisms of secondary resistance to tyrosine kinase inhibitors in
gastrointestinal stromal tumours (review). Oncol Rep. 2009;21(6):
1359-1366. https://doi.org/10.3892/or_00000361.
28. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance
to imatinib mesylate in gastrointestinal stromal tumors and activity of
the PKC412 inhibitor against imatinib-resistant mutants. Gastroenter-
ology. 2005;128(2):270-279. https://doi.org/10.1053/J.GASTRO.
2004.11.020.
29. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. Late
resistance to imatinib therapy in a metastatic gastrointestinal stromal
tumour is associated with a second KIT mutation. Br J Cancer. 2004;
90(11):2059-2061. https://doi.org/10.1038/sj.bjc.6601819.
30. Berman HM, Westbrook J, Feng Z, et al.. The Protein Data Bank.
http://www.rcsb.org/pdb/status.html. 2000.
31. Eswar N, Eramian D, Webb B, Shen M-Y, Sali A. Protein structure
modeling with MODELLER. Methods Mol Biol. 2008;426:145-159.
https://doi.org/10.1007/978-1-60327-058-8_8.
32. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F,
Andrejšali AA. Comparative protein structure modeling of genes and
genomes. www.annualreviews.org. 2000.
33. Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical
user interface for CHARMM. J Comput Chem. 2008;29(11):1859-
1865. https://doi.org/10.1002/jcc.20945.
34. Jo S, Cheng X, Islam SM, et al. CHARMM-GUI PDB manipulator for
advanced modeling and simulations of proteins containing non-
standard residues. Adv Protein Chem Struct Biol. 2014;96:235-265.
https://doi.org/10.1016/bs.apcsb.2014.06.002.
35. Lee J, Cheng X, Swails JM, et al. CHARMM-GUI input generator for
NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM
simulations using the CHARMM36 additive force field. J Chem Theory
Comput. 2016;12(1):405-413. https://doi.org/10.1021/acs.jctc.
5b00935.
36. van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE,
Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem.
2005;26:1701-1718. https://doi.org/10.1002/jcc.20291.
37. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C.
Comparison of multiple AMBER force fields and development of
improved protein backbone parameters. Proteins. 2006;65:712-725.
https://doi.org/10.1002/prot.21123.
38. Martín-García F, Papaleo E, Gomez-Puertas P, Boomsma W, Lindorff-
Larsen K. Comparing molecular dynamics force fields in the essential
subspace. Roccatano D. PLOS One. 2015;10(3):e0121114. https://
doi.org/10.1371/journal.pone.0121114.
39. Huang J, Rauscher S, Nawrocki G, et al. CHARMM36m: an
improved force field for folded and intrinsically disordered proteins.
Nat Methods. 2017;14(1):71-73. https://doi.org/10.1038/nmeth.
4067.
40. Joung IS, Cheatham TE. Determination of alkali and halide monova-
lent ion parameters for ese in explicitly solvated biomolecular simula-
tions. J Phys Chem B. 2008;112(30):9020-9041. https://doi.org/10.
1021/jp8001614.
41. Bussi G, Donadio D, Parrinello M. Canonical sampling through veloc-
ity rescaling. J Chem Phys. 2007;126(1):014101. https://doi.org/10.
1063/1.2408420.
42. Parrinello M, Rahman A. Polymorphic transitions in single crystals: a
new molecular dynamics method. J Appl Phys. 1981;52(12):7182-
7190. https://doi.org/10.1063/1.328693.
43. Van Gunsteren WF, Berendsen HJC. A leap-frog algorithm for sto-
chastic dynamics. Mol Simul. 1988;1:173-185. https://doi.org/10.
1080/08927028808080941.
44. Darden T, York D, Pedersen L. Particle mesh Ewald: an Nlog
(N) method for Ewald sums in large systems. J Chem Phys. 1993;98
(12):10089-10092. https://doi.org/10.1063/1.464397.
45. Hess B. P-LINCS: a parallel linear constraint solver for molecular sim-
ulation. J Chem Theory Comput. 2008 Jan;4(1):116-122. https://doi.
org/10.1021/ct700200b.
46. Kabsch W, Sander C. Dictionary of protein secondary structure: pat-
tern recognition of hydrogen-bonded and geometrical features. Bio-
polymers. 1983;22(12):2577-2637. https://doi.org/10.1002/bip.
360221211.
47. Kunzmann P, Hamacher K. Biotite: a unifying open source computa-
tional biology framework in python. BMC Bioinform. 2018;19(1):346.
https://doi.org/10.1186/s12859-018-2367-z.
12 SRIKAKULAM ET AL.
48. R Core Team. R: a language and environment for statistical computing.
Vienna, Austria: R foundation for statistical computing; 2017 https://
www.R-project.org/.
49. Gapsys V, de Groot BL. Optimal superpositioning of flexible molecule
ensembles. Biophys J. 2013;104(1):196-207. https://doi.org/10.
1016/j.bpj.2012.11.003.
50. McClendon CL, Friedland G, Mobley DL, Amirkhani H, Jacobson MP.
Quantifying correlations between allosteric sites in thermodynamic
ensembles. J Chem Theory Comput. 2009;5(9):2486-2502. https://doi.
org/10.1021/ct9001812.
51. Bastys T, Gapsys V, Doncheva NT, Kaiser R, de Groot BL,
Kalinina OV. Consistent prediction of mutation effect on drug
binding in HIV-1 protease using alchemical calculations. J Chem
Theory Comput. 2018;14(7):3397-3408. https://doi.org/10.1021/
acs.jctc.7b01109.
52. Krivobokova T, Briones R, Hub JS, Munk A, De Groot BL. Partial
least-squares functional mode analysis: application to the membrane
proteins AQP1, Aqy1, and CLC-ec1. Biophys J. 2012;103:786-796.
https://doi.org/10.1016/j.bpj.2012.07.022.
53. Tibshirani R, Walther G, Hastie T.. Estimating the Number of Clusters
in a Data Set Via the Gap Statistic. https://statweb.stanford.edu/
gwalther/gap.
54. Ketchen DJ, Shook CL. The application of cluster analysis in strategic
management research: an analysis and critique. Strateg Manag J.
1996;17(6):441-458. https://doi.org/10.1002/(SICI)1097-0266
(199606)17:6<441::AID-SMJ819>3.0.CO;2-G.
55. Zhao J, Quan H, Xu Y, Kong X, Jin L, Lou L. Flumatinib, a selective
inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resis-
tance of certain KIT mutants. Cancer Sci. 2014;105:117-125. https://
doi.org/10.1111/cas.12320.
56. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib
in gastrointestinal stromal tumor occurs through secondary gene
mutation. Clin Cancer Res. 2005;11(11):4182-4190. https://doi.org/
10.1158/1078-0432.CCR-04-2245.
57. Nishida T, Kanda T, Nishitani A, et al. Secondary mutations in the
kinase domain of the KIT gene are predominant in imatinib-resistant
gastrointestinal stromal tumor. Cancer Sci. 2008;99(4):799-804.
https://doi.org/10.1111/j.1349-7006.2008.00727.x.
58. Spitaleri G, Biffi R, Barberis M, et al. Inactivity of imatinib in gastroin-
testinal stromal tumors (GISTs) harboring a KIT activation-loop
domain mutation (exon 17 mutation pN822K). OncoTargets Ther.
2015;8:1997-2003. https://doi.org/10.2147/OTT.S81558.
59. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the
autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J Biol
Chem. 2004;279(30):31655-31663. https://doi.org/10.1074/jbc.
M403319200.
60. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell.
2002;109(3):275-282. https://doi.org/10.1016/S0092-8674(02)00741-9.
61. Kornev AP, Taylor SS. Defining the conserved internal architecture of
a protein kinase. Biochim Biophys Acta BBA - Proteins Proteomics.
2010;1804(3):440-444. https://doi.org/10.1016/J.BBAPAP.2009.
10.017.
62. Kornev AP, Taylor SS, Eyck LFT. A helix scaffold for the assembly of
active protein kinases. Proc Natl Acad Sci. 2008;105(38):14377-
14382. https://doi.org/10.1073/pnas.0807988105.
63. Aleksandrov A, Simonson T. Molecular dynamics simulations show
that conformational selection governs the binding preferences of
imatinib for several tyrosine kinases. J Biol Chem. 2010;285(18):
13807-13815. https://doi.org/10.1074/jbc.M110.109660.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Srikakulam SK, Bastys T, Kalinina OV.
A shift of dynamic equilibrium between the KIT active and
inactive states causes drug resistance. Proteins. 2020;1–13.
https://doi.org/10.1002/prot.25963
SRIKAKULAM ET AL. 13
